Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Date:3/20/2009

bination with a standard dosage of docetaxel. Eligible patients included those who have been diagnosed with advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The poster presentation will be available on the Oncolytics website today at www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analysis of the results of the REOLYSIN(R)/docetaxel trial and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize RE
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
2. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
3. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
4. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
5. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
6. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
8. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
9. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
10. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
11. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Sunnyvale, CA (PRWEB) May 21, 2013 ... is an 8-week training program starting on June ... to help clinical trial professionals reach the next step ... at Dentons Offices in Palo Alto, and streamed online. ... author of award-winning papers, Clinovo's new “CDISC Standards: Theory ...
(Date:5/20/2013)... May 21, 2013 Grace Century ... in “game-changing” life science and health related private equity ... to its International Project Team. Dergham's expertise in finance ... multi-cultural depth to Grace Century as it continues to ... , Ms. Dergham holds both an under graduate degree ...
(Date:5/20/2013)...  MiMedx Group, Inc. (NASDAQ: MDXG ), ... regenerative biomaterials and bioimplants processed from human amniotic membrane, ... of credit with Bank of America.  The revolving line ... accounts receivable and inventory, allows MiMedx to borrow up ... will be used for general corporate purposes. ...
(Date:5/20/2013)... 2013  (PSHR) Pacific Shore Holdings, Inc. a ... a broad range of product categories lines, today ... firm, BlueWater Advisory Group, to provide strategic counsel ... and to direct the company,s outreach and investor ... Matthew Mills , Pacific Shore Holdings, ...
Breaking Biology Technology:Clinovo Launches TechTrainings on CDISC Standards 2Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Pacific Shore Holdings Retains Investor Relations Firm 2
... a year-long "break" in Iraq, Matt Storms is ready to ... columns covered due diligence and corporate clean up, the mechanics ... Small Business Technology Transfer (STTR) grants. We thank Matt for ... to Wisconsin entrepreneurs. , , Once you complete ...
... acquisition would enable Johnson Controls, Inc. , ... automotive batteries annually, to expand its automotive aftermarket ... said. , ,In an arrangement the company is ... developing a next-generation hyrid car battery, will acquire ...
... Jellyfish.com has secured $5 million in a funding round ... Investments, LLC. , ,The funding will allow Jellyfish to ramp ... In conjunction with the funding, retail industry veteran Ralph Dillon, ... Board of Directors. , ,Jellyfish has gained traction in online ...
Cached Biology Technology:Raising capital through placement agents 2Raising capital through placement agents 3Raising capital through placement agents 4Online retailer Jellyfish.com lands $5M in funding 2Online retailer Jellyfish.com lands $5M in funding 3
(Date:5/21/2013)... developed a new method for delivering molecules into ... cell surface. The technique could find applications in ... , Bulk electroporation a technique used to ... the cell membrane that are caused by exposing ... popular method of cell transfection. (Cell transfection is ...
(Date:5/21/2013)... an uphill battle? Try staying fit in space, where ... and bone. , That,s the challenge a group of ... three-year, $1.2 million grant from NASA. Their goal is ... missions. , "You could give astronauts the best exercise ... to stick to it, it isn,t going to help," ...
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Fueling fitness on the final frontier 2Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... first study to link social evolution to climate change, Cornell ... of sweat bees evolved simultaneously during a period of global ... than scientists ever thought -- only 20 million to 22 ... insects, which evolved more than 65 million years ago. , ...
... affecting southern right whales (Eubalaena australis) in the South ... scientists found a strong relationship between breeding success of ... the western Pacific. The results are published this week ... whales migrate from the South Atlantic to the Southern ...
... bacterium in an immune-compromised patient, according to a study ... to the family Acetobacteraceae and includes bacteria common in ... such as vinegar-making. "This is the first reported ... the Acetobacteraceae," according to the article. , ...
Cached Biology News:Sociality of sweat bees evolved simultaneously during climate change 2Scientists discover a new disease-causing bacterium in an immune-compromised patient 2
... Service, We deliversoluble protein or No ... yields the best soluble protein results , ... clone submitted , Powerful results on your ... Solubility Optimization Service (SOS) uses proprietary tools ...
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... The ProteinChip beta-amyloid Multipeptide Kit, designed ... makes detecting a variety of amyloid ... ever before. - Clinical neuroscience proteomics ... drug treatment - Correlate beta-amyloid peptide ...
Formula variant: With the macro- and micronutrients as described by Lloyd and McCown (1981). Preparation Quantity Equivalency: Formulated to contain 2.3 grams of powder per liter of medium. Physical ...
Biology Products: